Algert Global LLC Arvinas, Inc. Transaction History

Algert Global LLC

$3.72 Billion
Q3 2024

A detailed history of Algert Global LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Algert Global LLC holds 168,061 shares of ARVN stock, worth $2.87 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares

168,061

Previous 44,448 278.11%

Holding current value

$2.87 Million

Previous $1.18 Million 249.87%

% of portfolio

0.11%

Previous 0.04%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$23.66 - $32.73 $2.92 Million - $4.05 Million	123,613 Added 278.11%	168,061 $4.14 Million
Q2 2024 Aug 14, 2024	SELL	$24.46 - $40.4 $91,651 - $151,378	-3,747 Reduced 7.77%	44,448 $1.18 Million
Q1 2024 May 14, 2024	SELL	$36.38 - $52.31 $959,558 - $1.38 Million	-26,376 Reduced 35.37%	48,195 $1.99 Million
Q4 2023 Feb 14, 2024	SELL	$14.19 - $42.33 $1.4 Million - $4.18 Million	-98,847 Reduced 57.0%	74,571 $3.07 Million
Q3 2023 Nov 13, 2023	BUY	$19.64 - $28.21 $1.07 Million - $1.53 Million	54,229 Added 45.5%	173,418 $3.41 Million
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $1.54 Million - $2.23 Million	70,837 Added 146.5%	119,189 $2.96 Million
Q1 2023 May 12, 2023	BUY	$26.15 - $37.26 $1.26 Million - $1.8 Million	48,352 New	48,352 $1.32 Million
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $338,182 - $534,561	-14,710 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$29.88 - $56.74 $333,610 - $633,502	-11,165 Reduced 43.15%	14,710 $493,000
Q1 2020 May 13, 2020	BUY	$33.0 - $54.5 $500,313 - $826,274	15,161 Added 141.51%	25,875 $1.04 Million
Q4 2019 Feb 18, 2020	BUY	$15.39 - $44.38 $164,888 - $475,487	10,714 New	10,714 $440,000

Others Institutions Holding ARVN

# of Institutions

227

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $910M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Arvinas, Inc. Transaction History